Biosimilars are also known as the innovator products, are copied products which are made similar to an original product. Biosimilars are mostly related to biologics and as compared to original products, a biosimilar doesn’t need to undergo a rigorous trial and approval process. In recent times, the use of biosimilars as a treatment option has increased a bit, but still, there are many patients who are deprived of these molecules.
They are thought to be a throw-away product but if the innovator products are not used as a biosimilar, the same molecule will lose its importance. In this exclusive interview, various aspects about biosimilars along with examples of insulin therapies has been thoroughly explained.
